CN116077580A - Uric acid reducing composition and preparation process thereof - Google Patents

Uric acid reducing composition and preparation process thereof Download PDF

Info

Publication number
CN116077580A
CN116077580A CN202211152099.8A CN202211152099A CN116077580A CN 116077580 A CN116077580 A CN 116077580A CN 202211152099 A CN202211152099 A CN 202211152099A CN 116077580 A CN116077580 A CN 116077580A
Authority
CN
China
Prior art keywords
mass
extract
uric acid
mixing
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211152099.8A
Other languages
Chinese (zh)
Inventor
卓林双
韩军涛
高梦
郝建林
刘子维
张晶晶
宋娟
赵珊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Tong Health Industry Hebei Co ltd
Original Assignee
Dr Tong Health Industry Hebei Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Tong Health Industry Hebei Co ltd filed Critical Dr Tong Health Industry Hebei Co ltd
Priority to CN202211152099.8A priority Critical patent/CN116077580A/en
Publication of CN116077580A publication Critical patent/CN116077580A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8967—Lilium, e.g. tiger lily or Easter lily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention discloses a uric acid reducing composition and a preparation process thereof, wherein the uric acid reducing composition comprises the following raw materials in parts by weight: 20-40% of maltodextrin by mass part; 15-30% of oligomeric maltose; 2-12% of taurine by mass portion; 4-9% of vitamin B1 by mass; 4-9% of vitamin B2 by mass; 6-12% of chicory powder by mass; 3-8% of lily extract by mass; 2 to 6 mass parts of streptococcus thermophilus STN 26; 5-11% of celery seed extract by mass; 2-14% of acerola cherry extract by mass part; the mass portion of the mint leaf extract is 1-5%. The invention effectively promotes the rapid discharge of urine of patients, increases the times of urination of the patients, thereby reducing the uric acid amount in the patients, avoiding the swelling phenomenon of the patients caused by gout, effectively helping to maintain normal uric acid level of the bodies, preventing the hyperuricemia of the patients and improving the gout symptom of the patients.

Description

Uric acid reducing composition and preparation process thereof
Technical Field
The invention relates to the technical field of health products, in particular to a uric acid reducing composition and a preparation process thereof.
Background
Stable uric acid levels in the body involve a balance between uric acid production, absorption, metabolism and decomposition, and clinical treatment of gout drugs is aimed at controlling the acute onset of symptoms, correcting hyperuricemia, preventing the recurrence of arthritis and the deposition of urate, protecting kidney function, etc.
According to patent 202011172735.4, it is known that a uric acid reducing composition and a preparation method thereof relate to the field of health-care food, and main functional components of the composition are theaflavin, resveratrol, dihydromyricetin, theanine and cordycepin in a set proportion, and the composition plays roles of reducing uric acid and resisting gout mainly by inhibiting xanthine oxidase activity, regulating the expression level of related anion transporter mRNA and protein and promoting uric acid excretion; meanwhile, the composition can relieve the matrix degradation of chondrocytes after IL-1 beta stimulation and reduce the expression of inflammatory factors, thereby relieving the symptoms of osteoarthritis and relieving the pain of the bone joints.
Currently, existing uric acid lowering compositions have some drawbacks, such as; the existing uric acid reducing composition cannot promote the rapid discharge of urine of a patient, the patient is easy to cause swelling caused by gout, the normal uric acid level of the body cannot be effectively maintained, the hyperuricemia of the patient is easy to occur, the blood circulation of the patient cannot be promoted, the effects of detumescence and pain relief cannot be achieved, and the patient cannot be helped to recover autonomous uric acid.
Disclosure of Invention
The invention aims to provide a uric acid reducing composition and a preparation process thereof, and solves the problems in the background technology.
In order to achieve the above purpose, the present invention provides the following technical solutions: the uric acid reducing composition and the preparation process thereof comprise the following raw materials in parts by weight: 20-40% of maltodextrin by mass part; 15-30% of oligomeric maltose; 2-12% of taurine by mass portion; 4-9% of vitamin B1 by mass; 4-9% of vitamin B2 by mass; 6-12% of chicory powder by mass; 3-8% of lily extract by mass; 2 to 6 mass parts of streptococcus thermophilus STN 26; 5-11% of celery seed extract by mass; 2-14% of acerola cherry extract by mass part; the mass portion of the mint leaf extract is 1-5%.
As a preferred embodiment of the invention, the uric acid reducing composition comprises the following raw materials in parts by weight: the mass portion of maltodextrin is 40%; 30 parts of oligomeric maltose; 2% of taurine by mass; 4 parts by mass of vitamin B1; 4 parts by mass of vitamin B2; 6% of chicory powder by mass; 3 parts of lily extract by mass; 2% of streptococcus thermophilus STN26 by mass; 5% of celery seed extract by mass; 3 parts of acerola cherry extract by mass; the mass portion of the mint leaf extract is 1%.
As a preferred embodiment of the invention, the uric acid reducing composition comprises the following raw materials in parts by weight: the mass portion of maltodextrin is 25%; 20 parts of oligomeric maltose; taurine 5 weight portions; 6 parts by mass of vitamin B1; 6 parts by mass of vitamin B2; 8% of chicory powder by mass; the lily extract is 5% by mass; 5% of streptococcus thermophilus STN26 by mass; 8% of celery seed extract by mass; 9 parts of acerola cherry extract by mass; the mass portion of the mint leaf extract is 3%.
As a preferred embodiment of the invention, the preparation process of the uric acid reducing composition comprises the following preparation steps:
a. weighing the raw materials according to parts by weight;
b. after the step a is completed, putting raw materials maltodextrin and isomaltooligosaccharide into a mixer to be mixed to prepare a mixture A, and then adding weighed taurine, vitamin B1 and vitamin B2 into the mixture A to be mixed to prepare a mixture B;
c. after the step b is completed, adding the weighed chicory powder, the lily extract and the streptococcus thermophilus STN26 into a mixer for mixing to obtain a mixture C, and adding the weighed celery seed extract, the needle cherry extract and the mint leaf extract into the mixer for mixing to obtain a mixture D;
d. c, after the step is completed, sequentially adding the prepared mixture B, the mixture C and the mixture D into a mixer to be mixed to prepare a composition blank, and then scattering and screening the mixed composition to prepare the uric acid reducing composition;
e. and d, after the step d is finished, finally, filling the prepared uric acid reducing composition into a capsule, and filling the capsule into a medicine bottle for packaging.
In a preferred embodiment of the present invention, the raw material maltodextrin and the oligomaltose in the step B are placed into a mixer for mixing, the rotation speed during mixing is 1200-1500 r/min, the mixing time is 5-8 min, the weighed taurine, vitamin B1 and vitamin B2 are added into the mixture A for mixing, the rotation speed during mixing is 300-400 r/min, the mixing time is 3-6 min, and the temperature during mixing is 20-30 ℃.
As a preferred embodiment of the invention, in the step c, the weighed chicory powder, the lily extract and the streptococcus thermophilus STN26 are added into a mixer for mixing, the rotation speed during mixing is 500-600 r/min, the mixing time is 7-12 min, the temperature during mixing is 20-30 ℃, the weighed celery seed extract, the needle cherry extract and the mint leaf extract are added into the mixer for mixing, the rotation speed during mixing is 300-400 r/min, the mixing time is 3-6 min, and the temperature during mixing is 20-30 ℃.
As a preferred embodiment of the invention, the prepared mixture B, the prepared mixture C and the prepared mixture D are sequentially added into a mixer for mixing in the step D, the rotating speed is 600-900 r/min, the mixing time is 20-30 min, and the temperature is 35-45 ℃.
As a preferred embodiment of the present invention, the weight of each capsule in the step e is 0.45g-0.60g,30 capsules/bottle.
Compared with the prior art, the invention has the following beneficial effects:
1. according to the invention, through the combination of chicory powder, lily extract and streptococcus thermophilus STN26, the effect of rapidly discharging urine of a patient is effectively promoted, and the urination frequency of the patient is increased, so that the uric acid amount in the patient is reduced, the swelling phenomenon of the patient caused by gout is avoided, the normal uric acid level of the body is effectively maintained, the hyperuricemia of the patient is prevented, and the improvement effect of gout symptoms of the patient is improved.
2. By combining the celery seed extract, the acerola cherry extract and the mint leaf extract, the invention has the effects of resisting inflammation, easing pain and obviously reducing serum uric acid, promotes the blood circulation of patients, can relieve discomfort caused by gout and arthritis, can reduce the probability of inflammation, plays the roles of detumescence and relieving pain, and can also help the patients to recover autonomous uric acid.
Detailed Description
The technical solutions of the embodiments of the present invention are clearly and completely described, and it is obvious that the described embodiments are only some embodiments of the present invention, but not all embodiments.
Example 1
The uric acid reducing composition comprises the following raw materials in parts by weight: the mass portion of maltodextrin is 40%; 30 parts of oligomeric maltose; 2% of taurine by mass; 4 parts by mass of vitamin B1; 4 parts by mass of vitamin B2; 6% of chicory powder by mass; 3 parts of lily extract by mass; 2% of streptococcus thermophilus STN26 by mass; 5% of celery seed extract by mass; 3 parts of acerola cherry extract by mass; the mass portion of the mint leaf extract is 1%.
The preparation method comprises the following steps:
a. weighing the raw materials according to parts by weight;
b. after the step a is completed, the raw materials maltodextrin and the low-polymer maltose are put into a mixer for mixing, the rotating speed is 1300r/min when mixing, the mixing time is 6min, a mixture A is prepared, then the weighed taurine, the vitamin B1 and the vitamin B2 are added into the mixture A for mixing, the rotating speed is 350r/min when mixing, the mixing time is 5min, and the temperature is 25 ℃ when mixing, so that a mixture B is prepared;
c. after the step b is completed, adding the weighed chicory powder, the lily extract and the streptococcus thermophilus STN26 into a mixer for mixing, wherein the rotating speed is 550r/min, the mixing time is 9min, the temperature is 25 ℃ during mixing to prepare a mixture C, adding the weighed celery seed extract, the acerola cherry extract and the mint leaf extract into the mixer for mixing, the rotating speed is 350r/min, the mixing time is 5min, and the temperature during mixing is 25 ℃ to prepare a mixture D;
d. c, after the step is completed, sequentially adding the prepared mixture B, the mixture C and the mixture D into a mixer for mixing, wherein the rotating speed is 850r/min, the mixing time is 25min, the temperature is 40 ℃ during mixing to prepare a composition blank, and then scattering and screening the mixed composition to prepare the uric acid reducing composition;
e. and d, after the step d is finished, finally, filling the prepared uric acid reducing composition into capsules, filling the capsules into medicine bottles for packaging, wherein the weight of each capsule is 0.45g-0.60g and 30 capsules/bottle.
Example two
The uric acid reducing composition comprises the following raw materials in parts by weight: the mass portion of maltodextrin is 25%; 20 parts of oligomeric maltose; taurine 5 weight portions; 6 parts by mass of vitamin B1; 6 parts by mass of vitamin B2; 8% of chicory powder by mass; the lily extract is 5% by mass; 5% of streptococcus thermophilus STN26 by mass; 8% of celery seed extract by mass; 9 parts of acerola cherry extract by mass; the mass portion of the mint leaf extract is 3%.
The preparation method comprises the following steps:
a. weighing the raw materials according to parts by weight;
b. after the step a is completed, the raw materials maltodextrin and the low-polymer maltose are put into a mixer for mixing, the rotating speed is 1300r/min when mixing, the mixing time is 6min, a mixture A is prepared, then the weighed taurine, the vitamin B1 and the vitamin B2 are added into the mixture A for mixing, the rotating speed is 350r/min when mixing, the mixing time is 5min, and the temperature is 25 ℃ when mixing, so that a mixture B is prepared;
c. after the step b is completed, adding the weighed chicory powder, the lily extract and the streptococcus thermophilus STN26 into a mixer for mixing, wherein the rotating speed is 550r/min, the mixing time is 9min, the temperature is 25 ℃ during mixing to prepare a mixture C, adding the weighed celery seed extract, the acerola cherry extract and the mint leaf extract into the mixer for mixing, the rotating speed is 350r/min, the mixing time is 5min, and the temperature during mixing is 25 ℃ to prepare a mixture D;
d. c, after the step is completed, sequentially adding the prepared mixture B, the mixture C and the mixture D into a mixer for mixing, wherein the rotating speed is 850r/min, the mixing time is 25min, the temperature is 40 ℃ during mixing to prepare a composition blank, and then scattering and screening the mixed composition to prepare the uric acid reducing composition;
e. and d, after the step d is finished, finally, filling the prepared uric acid reducing composition into capsules, filling the capsules into medicine bottles for packaging, wherein the weight of each capsule is 0.45g-0.60g and 30 capsules/bottle.
Data parameters of the traditional uric acid lowering composition are shown in table 1 below:
test item Times of urination Uric acid content Anti-inflammatory effect Analgesic effect
Parameter index 3 times per day High height Poor quality In general
Example one uric acid lowering composition data parameters table 2 is as follows:
test item Times of urination Uric acid content Anti-inflammatory effect Analgesic effect
Parameter index 5 times per day Lower level Good quality Good quality
Example two uric acid lowering compositions data parameters table 3 is as follows:
test item Times of urination Uric acid content Anti-inflammatory effect Analgesic effect
Parameter index 7 times per day Low and low Excellent (excellent) Excellent (excellent)
In summary, the invention has the effects of effectively promoting the rapid discharge of urine of patients, increasing the urination times of patients, reducing the uric acid amount in the patients, avoiding the swelling phenomenon caused by gout of the patients, effectively helping to maintain normal uric acid level of the bodies, preventing hyperuricemia of the patients, improving the gout symptom of the patients, resisting inflammation, easing pain and obviously reducing serum uric acid, promoting the blood circulation of the patients, relieving discomfort caused by gout and arthritis, reducing the probability of inflammation, playing the roles of detumescence and relieving pain, and helping the patients to recover autonomous uric acid.
While the fundamental and principal features of the invention and advantages of the invention have been shown and described, it will be apparent to those skilled in the art that the invention is not limited to the details of the foregoing exemplary embodiments, but may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Furthermore, it should be understood that although the present disclosure describes embodiments, not every embodiment is provided with a separate embodiment, and that this description is provided for clarity only, and that the disclosure is not limited to the embodiments described in detail below, and that the embodiments described in the examples may be combined as appropriate to form other embodiments that will be apparent to those skilled in the art.

Claims (8)

1. A uric acid lowering composition characterized by: comprises the following raw materials in parts by weight: 20-40% of maltodextrin by mass part; 15-30% of oligomeric maltose; 2-12% of taurine by mass portion; 4-9% of vitamin B1 by mass; 4-9% of vitamin B2 by mass; 6-12% of chicory powder by mass; 3-8% of lily extract by mass; 2 to 6 mass parts of streptococcus thermophilus STN 26; 5-11% of celery seed extract by mass; 2-14% of acerola cherry extract by mass part; the mass portion of the mint leaf extract is 1-5%.
2. The uric acid lowering composition of claim 1, wherein: comprises the following raw materials in parts by weight: the mass portion of maltodextrin is 40%; 30 parts of oligomeric maltose; 2% of taurine by mass; 4 parts by mass of vitamin B1; 4 parts by mass of vitamin B2; 6% of chicory powder by mass; 3 parts of lily extract by mass; 2% of streptococcus thermophilus STN26 by mass; 5% of celery seed extract by mass; 3 parts of acerola cherry extract by mass; the mass portion of the mint leaf extract is 1%.
3. The uric acid lowering composition of claim 1, wherein: comprises the following raw materials in parts by weight: the mass portion of maltodextrin is 25%; 20 parts of oligomeric maltose; taurine 5 weight portions; 6 parts by mass of vitamin B1; 6 parts by mass of vitamin B2; 8% of chicory powder by mass; the lily extract is 5% by mass; 5% of streptococcus thermophilus STN26 by mass; 8% of celery seed extract by mass; 9 parts of acerola cherry extract by mass; the mass portion of the mint leaf extract is 3%.
4. The process for preparing uric acid lowering composition as defined in claim 1, wherein: the preparation method comprises the following steps:
a. weighing the raw materials according to parts by weight;
b. after the step a is completed, putting raw materials maltodextrin and isomaltooligosaccharide into a mixer to be mixed to prepare a mixture A, and then adding weighed taurine, vitamin B1 and vitamin B2 into the mixture A to be mixed to prepare a mixture B;
c. after the step b is completed, adding the weighed chicory powder, the lily extract and the streptococcus thermophilus STN26 into a mixer for mixing to obtain a mixture C, and adding the weighed celery seed extract, the needle cherry extract and the mint leaf extract into the mixer for mixing to obtain a mixture D;
d. c, after the step is completed, sequentially adding the prepared mixture B, the mixture C and the mixture D into a mixer to be mixed to prepare a composition blank, and then scattering and screening the mixed composition to prepare the uric acid reducing composition;
e. and d, after the step d is finished, finally, filling the prepared uric acid reducing composition into a capsule, and filling the capsule into a medicine bottle for packaging.
5. The process for preparing uric acid lowering composition as defined in claim 4, wherein: and B, putting the raw materials maltodextrin and the isomaltooligosaccharide into a mixer for mixing, wherein the rotating speed during mixing is 1200-1500 r/min, the mixing time is 5-8 min, the weighed taurine, vitamin B1 and vitamin B2 are added into the mixture A for mixing, the rotating speed during mixing is 300-400 r/min, the mixing time is 3-6 min, and the mixing temperature is 20-30 ℃.
6. The process for preparing uric acid lowering composition as defined in claim 4, wherein: in the step c, the weighed chicory powder, the lily extract and the streptococcus thermophilus STN26 are added into a mixer for mixing, the rotation speed is 500-600 r/min, the mixing time is 7-12 min, the temperature is 20-30 ℃ during mixing, the weighed celery seed extract, the needle cherry extract and the mint leaf extract are added into the mixer for mixing, the rotation speed is 300-400 r/min, the mixing time is 3-6 min, and the temperature is 20-30 ℃ during mixing.
7. The process for preparing uric acid lowering composition as defined in claim 4, wherein: and in the step D, the prepared mixture B, the prepared mixture C and the prepared mixture D are sequentially added into a mixer for mixing, the rotating speed during mixing is 600-900 r/min, the mixing time is 20-30 min, and the temperature during mixing is 35-45 ℃.
8. The process for preparing uric acid lowering composition as defined in claim 4, wherein: the weight of each capsule in the step e is 0.45g-0.60g,30 capsules/bottle.
CN202211152099.8A 2022-09-21 2022-09-21 Uric acid reducing composition and preparation process thereof Pending CN116077580A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211152099.8A CN116077580A (en) 2022-09-21 2022-09-21 Uric acid reducing composition and preparation process thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211152099.8A CN116077580A (en) 2022-09-21 2022-09-21 Uric acid reducing composition and preparation process thereof

Publications (1)

Publication Number Publication Date
CN116077580A true CN116077580A (en) 2023-05-09

Family

ID=86201289

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211152099.8A Pending CN116077580A (en) 2022-09-21 2022-09-21 Uric acid reducing composition and preparation process thereof

Country Status (1)

Country Link
CN (1) CN116077580A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109452521A (en) * 2018-12-26 2019-03-12 广东养慕特殊医用食品有限公司 A kind of anti-trioxypurine peptide solid beverage, Preparation method and use
CN111617231A (en) * 2019-11-01 2020-09-04 北京同仁堂健康药业股份有限公司 Uric acid-reducing and anti-gout composition as well as preparation method and application thereof
CN113249280A (en) * 2021-07-16 2021-08-13 中科嘉亿营养医学(山东)微生态研究院有限公司 Streptococcus thermophilus STN26, bacterium powder and application in uric acid reducing product

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109452521A (en) * 2018-12-26 2019-03-12 广东养慕特殊医用食品有限公司 A kind of anti-trioxypurine peptide solid beverage, Preparation method and use
CN111617231A (en) * 2019-11-01 2020-09-04 北京同仁堂健康药业股份有限公司 Uric acid-reducing and anti-gout composition as well as preparation method and application thereof
CN113249280A (en) * 2021-07-16 2021-08-13 中科嘉亿营养医学(山东)微生态研究院有限公司 Streptococcus thermophilus STN26, bacterium powder and application in uric acid reducing product

Similar Documents

Publication Publication Date Title
US11464821B2 (en) Composition for reducing cancer cachexia or weight loss caused by anticancer drug therapy or radiation therapy comprising ginseng extract having increased ginsenoside Rg3 and Rh2
CN101132697A (en) Weight loss composition and method of inducing weight loss
CN110420293A (en) The plant composition and plant composition solid particle for treating hyperuricemia and gout
CN110604303A (en) Rhizoma polygonati paste and preparation method thereof
CN116077580A (en) Uric acid reducing composition and preparation process thereof
CN101744852B (en) Preparation method of acanthopanax effervescent tablet and products thereof
CN105943958A (en) Inonotus obliquus composite solid particles for treating gout and preparing method thereof
CN107095858A (en) A kind of urso capsule and preparation method thereof
CN112451476A (en) Tomoxetine hydrochloride oral liquid and preparation method thereof
CN107157943B (en) Topiroxostat preparation and preparation method thereof
CN112189849A (en) Uric acid reducing composition and preparation method thereof
CN107115307A (en) A kind of Loratadine tablet and preparation method thereof
CN113116915A (en) Composition of marsdenia tenacissima glycoside H and paclitaxel and application thereof
CN103142587B (en) Amoxicillin sodium-potassium clavulanate pharmaceutical composition and preparation method thereof
CN102626420B (en) Mixed preparation containing strontium, calcium and vitamin D
CN113318142A (en) Formula containing olive extract and preparation method and application thereof
CN116585379B (en) Traditional Chinese medicine composition, method and application for preventing and treating hyperuricemia and gout
CN114533700B (en) Naproxen oral preparation and preparation method thereof
CN114832004B (en) Pharmaceutical composition for treating metabolic abnormality and preparation method thereof
LU500641B1 (en) A pharmaceutical composition for treating depression
KR20020061307A (en) Manufacturing process of a capsule tea
JP7440730B2 (en) Application in the preparation of pharmaceutical compositions and anti-osteoporotic drugs
CN111419802B (en) Febuxostat-containing pharmaceutical composition and preparation method thereof
CN107279620A (en) A kind of electrolyte beverage composition and preparation method thereof
CN117298095B (en) Application of eupatorium sesquiterpene lactone compounds in preparation of medicines for treating/preventing NLRP3 inflammatory small body mediated diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination